FDA approves Wegovy to reduce heart attack and stroke risk

The blockbuster weight loss drug Wegovy is now approved to reduce heart disease risk, drugmaker Novo Nordisk said Friday. The Food and Drug Administration has updated the drug's label, saying that Wegovy can be prescribed to reduce a person's risk of heart attack and stroke, the company said. Heart disease is the leading cause of death in the United States, according to the Centers for Disease Control and Prevention.

All of the people in the trial were overweight or had obesity, and had a history of heart disease. The label change could mean that more employers and insurers are persuaded to cover the medication. Many have been hesitant to cover the pricy drug for weight loss. Wegovy, along with other weight loss medications, such as Eli Lilly's Zepbound, are typically not covered by insurance; Medicare, by law, is barred from covering them.

Health Health Latest News, Health Health Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Novo Nordisk settles two lawsuits over copycat versions of Ozempic and WegovyBerkeley Lovelace Jr. is a health and medical reporter for NBC News. He covers the Food and Drug Administration, with a special focus on Covid vaccines, prescription drug pricing and health care. He previously covered the biotech and pharmaceutical industry with CNBC.
Source: NBCNewsHealth - 🏆 707. / 51 Read more »

More teens are using weight loss drugs like Wegovy and OzempicMarina Kopf is an associate producer with the NBC News Health and Medical Unit.
Source: NBCNewsHealth - 🏆 707. / 51 Read more »

Novo Nordisk’s New Obesity Pill Beats Wegovy In Early TrialI am a senior reporter for the Forbes breaking news team, covering health and science from the London office. Previously I worked as a reporter for a trade publication covering big data and law and as a freelance journalist and policy analyst covering science, tech and health.
Source: Forbes - 🏆 394. / 53 Read more »